A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of REGN20934 in Adult Participants With Overweight or Obesity
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:
• Has a Body Mass Index (BMI) 25 to 35 kg/m\^2
• Females must be of non-childbearing potential
Locations
United States
California
California Clinical Trials Medical Group
RECRUITING
Glendale
Contact Information
Primary
Clinical Trials Administrator
clinicaltrials@regeneron.com
844-734-6643
Time Frame
Start Date: 2026-06-29
Estimated Completion Date: 2027-02-22
Participants
Target number of participants: 90
Treatments
Experimental: REGN20934
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: Regeneron Pharmaceuticals